Close Menu

Linda Avey from 23andMe appeared on CNBC's Healthy Horizons to discuss her company. The host asks Avey what she would say to critics who say the diseases arise from complex interactions of genes and environment and that what 23andMe provides is a small amount of information that could be misinterpreted. Avey replies: "We think that's poppycock. We think we should really be able to engage people directly."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.